Advertisement

Topics

FDA Steps in to Manage Withdrawal of Daclizumab (Zinbryta)

13:09 EDT 14 Mar 2018 | Medscape

Already withdrawn voluntarily by the company and subject to suspension and recall in Europe, the FDA today announced it is 'working closely' to ensure a 'well organized withdrawal' of daclizumab in the United States.
News Alerts

Original Article: FDA Steps in to Manage Withdrawal of Daclizumab (Zinbryta)

NEXT ARTICLE

More From BioPortfolio on "FDA Steps in to Manage Withdrawal of Daclizumab (Zinbryta)"

Advertisement
Quick Search
Advertisement
Advertisement